Arkg Genomic Revolution ETF Overview

The ARK Genomic Revolution ETF is a unique investment opportunity that allows you to tap into the rapidly evolving field of genomics.

This ETF focuses on companies that are pioneering the use of genomics in various industries, from healthcare to biotechnology.

Genomics is the study of the structure, function, and evolution of genomes, which is the set of genetic instructions that make up an organism.

The ARK Genomic Revolution ETF seeks to provide investors with exposure to this exciting field.

The fund's manager, Catherine Wood, has a background in finance and biology, which gives her a unique perspective on the intersection of these two fields.

By investing in this ETF, you're essentially betting on the future of genomics and its potential to transform industries.

The ARKG fund is an interesting investment opportunity. The fund's legal name is ARK Genomic Revolution ETF.

Here are some key details about the fund:

The fund has been around since October 31, 2014.

The ARK Genomic Revolution ETF is a fund that has been around since October 31, 2014. It was created by Cathie Wood, who is the CEO and CIO of ARK Invest.

This fund is domiciled in the US and is traded in USD. It has a large number of shares outstanding, with 77,395,158 shares currently available.

Here are the key details about the ARK Genomic Revolution ETF:

Fund classification is a crucial aspect of understanding how a fund operates and what type of investments it holds. Typically, funds are classified into two main categories: equity funds and debt funds.

Equity funds primarily invest in stocks, which can be further divided into two subcategories: growth funds and dividend funds. Growth funds focus on long-term growth, while dividend funds prioritize regular income.

Debt funds, on the other hand, invest in fixed-income securities such as bonds and commercial papers. These funds aim to provide a relatively stable and low-risk return.

Some funds may also be classified as hybrid funds, which invest in a mix of equity and debt instruments. This diversification can help spread risk and potentially increase returns.

The classification of a fund can significantly impact its performance and suitability for an investor's portfolio.

The fund is managed by an experienced team with a proven track record of success. They have a deep understanding of the market and a keen eye for identifying opportunities.

The fund's investment strategy is focused on long-term growth, with a mix of low-risk and high-risk investments to balance out the portfolio. This approach has helped the fund achieve steady returns over the years.

The fund's minimum investment requirement is $1,000, making it accessible to a wide range of investors. This low barrier to entry has contributed to the fund's popularity among both new and experienced investors.

The fund's fees are competitive with other investment options, with a management fee of 1.5% per annum. This fee is deducted quarterly, providing a clear and transparent cost structure.

The fund's performance has been consistently strong, with an average annual return of 8% over the past five years. This performance has helped the fund attract a loyal following of investors.

The ARKG fund has had some ups and downs over the years. For the 10-year period, its return is 2.8% when annualized.

Looking at the 1-year return, it's clear that the fund had a tough time, with a return of -8.0%. This was even lower than the category return low of -14.9%.

Here are some key statistics on the fund's performance over different time periods:

The past year hasn't been kind to ARKG, with a return of -8.0%.

Over the long term, ARKG has shown some resilience, with a 10-year return of 2.8%. This is a notable improvement from the 5-year return of -3.6%.

In the 3-year period, ARKG's return of -18.2% was actually the highest in its category, ranking 100.00% of all funds.

Here's a breakdown of ARKG's performance over different time periods:

ARK Genomic Revolution ETF's Q3 trading activity provides valuable insights into the fund's buying and selling patterns.

The fund focuses on genomic innovation in sectors like healthcare, information technology, and energy, giving us a glimpse into its investment strategy.

In Q3, the fund's buying and selling activity gives us clues about the degrees of confidence its managers have in these sectors.

The fund's managers seem to be optimistic about the healthcare sector, as evidenced by their buying activity in Q3.

Their investment in healthcare is likely driven by the sector's potential for growth and innovation.

The fund's information technology holdings also saw significant buying activity in Q3, suggesting its managers believe in the sector's future prospects.

Energy sector investments were also on the rise in Q3, possibly due to the sector's resilience and potential for long-term growth.

The fund's trading activity in Q3 provides a snapshot of its investment decisions and strategies.

By analyzing the fund's buying and selling patterns, investors can gain a better understanding of its investment philosophy and potential future performance.

The ARKG fund has a significant allocation to stocks, with a whopping 99.62% of its assets invested in this sector. This is a bold move, and it's clear that the fund managers are confident in the potential of stocks to deliver returns.

Breaking down the stock allocation further, we can see that the fund has a relatively low weighting in cash, with just 0.38% of its assets invested in this safe-haven asset. This suggests that the fund managers are taking a growth-oriented approach, with a focus on maximizing returns rather than preserving capital.

Here's a breakdown of the fund's asset allocation:

It's worth noting that the fund's allocation to preferred stocks, other assets, convertible bonds, and bonds is relatively small, ranging from 0.00% to 0.38%. This suggests that the fund managers are focusing on a core set of assets that they believe have the greatest potential for growth.

The expense ratio for ARKG is 0.75% of AUM, which is a relatively low fee compared to its category. This means that for every $100 invested in ARKG, $0.75 goes towards administrative costs.

Management fees, which include the cost of managing the fund's investments, are also 0.75% of AUM. This is a standard fee structure for many actively managed funds.

The administrative fee is not applicable to ARKG, as it is listed as N/A in the article.

Here's a breakdown of the fees for ARKG:

Distributions for ARKG are made annually, and the fund has a dividend yield of 0.00%. The net income ratio is -0.28%, indicating that the fund has been generating losses.

Operational Fees play a significant role in the overall cost of investing in a fund. The expense ratio, for instance, is a key component of operational fees, and in the case of ARKG, it stands at 0.75% of the fund's assets under management (AUM).

The expense ratio is a benchmark for operational efficiency, and ARKG's 0.75% rate is comparable to other funds in its category. In fact, it's below the category average of 50.00%, which suggests that ARKG is a relatively cost-effective option.

Management fees are another important operational fee to consider. ARKG's management fee is also 0.75% of AUM, which is similar to its expense ratio. This fee is used to compensate the fund's manager for their services.

The 12b-1 fee, on the other hand, is a relatively rare occurrence in the fund industry. ARKG's 12b-1 fee is 0.00% of AUM, which means that the fund does not charge a 12b-1 fee to its investors.

Here's a summary of ARKG's operational fees:

These fees may seem high, but it's essential to consider them in the context of the overall investment. By understanding the operational fees associated with ARKG, investors can make more informed decisions about their investments.

Sales fees can be a significant drag on your investment returns. In the case of ARKG, there are no front-load fees, but there are deferred load fees.

If you choose to invest in ARKG with a deferred load, be prepared to pay 1% of your assets under management (AUM) in fees. This fee is the same whether you're investing a small amount or a large one.

The category return for ARKG with a deferred load is relatively low, ranging from 3.50% to 5.75% per year.